Scholars Central

Conference abstractPublished 8 Nov 2021

Clinical benefits of single vs repeated courses of mesenchymal stem cell therapy in epilepsy patients

Authors: Tatiana Dakukina

Ask about this article

Abstract

Select any words in the title or abstract, or press this and choose a sentence.

Epilepsy is defined as “refractory” when existing anti-epileptic drugs (AED) are found to have minimal to no effect on patient’s condition. Therefore the search and testing of new treatment strategies is warranted. The “two-hit” strategy using autologous mesenchymal stem cells (MSC) was offered to patients with symptomatic drug-resistant epilepsy within a Phase I/II open-label registered clinical trial NCT0247443. The patients received either standard treatment with AEDs (control group, n=33), or AEDs supplemented with one or two courses of therapy with autologous bone marrow-derived MSCs, expanded in vitro (MSC group, n=34). MSC therapy courses were 6 months apart, and each course consisted of two cell injections: an intravenous infusion of MSCs, followed within 1 week by an intrathecal administration of neurally differentiated MSCs. MSC injections proved safe without any severe side effects. In MSC group, 61.7% patients responded to therapy at 6 months timepoint (p<0.01 vs control), and the number rose to 76.5% by 12 months timepoint. Decrease in anxiety and depression scores and paroxysmal epileptiform activity was observed in MSC group based on HADS and EEG, respectively, and MMSE score has also improved. Concomitant administration of levetiracetam, but not other AEDs, correlated with the success of MSC therapy. Second course of MSC therapy facilitated further reduction in seizure count and epileptiform EEG activity (p<0.05 vs single course). Application of autologous MSC based therapy in patients with pharmacoresistant epilepsy demonstrated significant anticonvulsant potential. This effect lasted for at least one year, with repeated administration of MSCs conveying additional clinical benefit.

Ask about this article

Answers come only from this article's title, abstract and keywords, each sentence pointing to where it comes from. Your question is sent to OpenAI to write the answer. Scholars Central does not store it.

Try:

More from this journal

The newest in Journal of Stem Cell Research & Therapy.

All its articles

Conferences in this field

Upcoming conferences in this field.

Follow

New articles from what you follow go into your email digest, once you agree to alert emails.

  • JournalJournal of Stem Cell Research & Therapy
  • SubjectGenetics & Molecular Biology
  • BylineArticles whose byline prints “Tatiana Dakukina”